DADC
TARS icon

D.A. Davidson & Co’s Tarsus Pharmaceuticals TARS Stock Holding History

D.A. Davidson & Co’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Sell
15,966
-927
-5% -$59.2K 0.01% 964
2026
Q1 		$1.19M Sell
16,893
-1,340
-7% -$93.6K 0.01% 866
2025
Q4 		$1.49M Buy
+18,233
New +$1.36M 0.01% 761

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.A. Davidson & Co's TARS Position: Q2 2026 in Review

D.A. Davidson & Co reduced its Tarsus Pharmaceuticals (TARS) stake by 5.5% in Q2 2026, selling an estimated $59.2K and leaving 15,966 shares worth $1M. The position accounts for 0.01% of the portfolio, ranked #964.

D.A. Davidson & Co first reported a position in TARS in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.49M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • D.A. Davidson & Co held 15,966 shares of Tarsus Pharmaceuticals worth $1M as of Q2 2026.
  • D.A. Davidson & Co sold 927 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $59.2K.
  • Tarsus Pharmaceuticals made up 0.01% of D.A. Davidson & Co's portfolio in Q2 2026, its #964 holding.
  • D.A. Davidson & Co first reported a position in Tarsus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • D.A. Davidson & Co's Tarsus Pharmaceuticals position peaked at $1.49M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.